and dominates the CF market and will do so for many years. Insmeds entry in Europe will be a very small revenue base.If Insmed achieves revenues from CF by 2019 of over 25 million,everyone will be surprised.the novartis post is for idiots who need info.You assume approval.EU may want to wait for more data
You will get a lot of jerks that post who will attack you but Arikace is a very small money maker.Arikace will not even be sold in the USA! NTM is the whole game for INSM. For revenue realism Novartis dry power is taking control of the market.Once a day is not a big deal to insurance cos Price and availability are.